The PrismIx platform identifies subsets of patients within a certain disease, clearly showing that patients cannot be treated uniformly. We develop PrismDx tests to identify the groups of patients who will not respond to certain drugs so they can be prescribed alternative therapies and PrismRx finds new targets to help treat specific groups of patients who do not respond to drugs currently on the market.
We’re developing tests that predict drug response to help patients get the treatment that is more likely to work for them. Tumor Necrosis Factor inhibitors (anti-TNFs) are the largest selling drug in the world with low response rates and come with potentially serious side effects, so we started here.
PrismRA identifies patients with rheumatoid arthritis (RA) who will likely not respond to anti-TNFs.
PrismUC identifies patients with ulcerative colitis (UC) who will likely not respond to anti-TNFs.
We have identified multiple targets for potential new drugs in IBD and tested them in with our lab partner on mouse and human assays.
PrismIx had a 120% higher hit rate than experts’ literature searches.